Therapy of moderate-to-severe Graves’ orbitopathy with intravenous methylprednisolone pulses is not associated with loss of bone mineral density

• DOI: 10.1007/s12020-018-1823-x
• Publication Date: 2018-12-01T21:40:20Z
• Authors: Joanna Rymuza; Michał Popow; Zuzanna Żurecka; Jerzy Przedlacki; Tomasz Bednarczuk; Piotr Miśkiewicz
• Keywords: Adult; Lumbar Vertebrae; Femur Neck; Middle Aged; Methylprednisolone; 3. Good health; Graves Ophthalmopathy; Young Adult; 03 medical and health sciences; Absorptiometry, Photon; 0302 clinical medicine; Bone Density; Humans; Osteoporosis; Original Article; Glucocorticoids; Aged

To evaluate the influence of intravenous methylprednisolone (IVMP) pulse administration on bone mineral density (BMD) lumbar spine and femoral neck in patients with moderate-to-severe Graves' orbitopathy (GO).Thirty-five GO euthyreosis were treated 12 IVMP pulses (6 × 0.5 g, 6 0.25 g a weekly schedule). Supplementation 1.0 calcium 800 IU vitamin D was initiated all before beginning therapy. BMD (L1-L4) assessed at baseline after last using dual-energy X-ray absorptiometry. determine differences between values treatment, we used least significant change (LSC) methodology. LSC calculated to be 3 5% for neck, respectively. Change equal or exceeding as either increase decrease BMD. We then compared pre-treatment post-treatment mean neck.We did not observe any site LSC. found an one measurement value 43% patients, mostly (31%). Mean while increased.IVMP given does lead loss neck.